Jeremy Grantham's UTHR Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 15,068 shares of United Therapeutics Corporation (UTHR) worth $6.32 M, representing 0.02% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Jeremy Grantham has maintained a strategic position in UTHR, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2020, adding 34,007 shares. Largest reduction occurred in Q4 2020, reducing 24,700 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2017 | +1,500 | New Buy | 1,500 | $135.33 |
| Q2 2017 | +900 | Add 60.00% | 2,400 | $129.58 |
| Q1 2018 | +3,600 | Add 150.00% | 6,000 | $112.33 |
| Q2 2018 | +200 | Add 3.33% | 6,200 | $113.23 |
| Q1 2019 | -500 | Reduce 8.06% | 5,700 | $117.37 |
| Q2 2019 | -5,700 | Sold Out | 5,700 | $0.00 |
| Q1 2020 | +8,300 | New Buy | 8,300 | $94.82 |
| Q2 2020 | -2,400 | Reduce 28.92% | 5,900 | $121.02 |
| Q3 2020 | +34,007 | Add 576.39% | 39,907 | $101.01 |
| Q4 2020 | -24,700 | Reduce 61.89% | 15,207 | $151.77 |
| Q1 2021 | -9,100 | Reduce 59.84% | 6,107 | $167.35 |
| Q2 2021 | -4,039 | Reduce 66.14% | 2,068 | $179.40 |
| Q3 2021 | -2,068 | Sold Out | 2,068 | $0.00 |
| Q1 2024 | +7,236 | New Buy | 7,236 | $229.72 |
| Q2 2024 | +21,486 | Add 296.93% | 28,722 | $318.55 |
| Q3 2024 | -24,634 | Reduce 85.77% | 4,088 | $358.35 |
| Q4 2024 | +4,139 | Add 101.25% | 8,227 | $352.84 |
| Q1 2025 | -5,705 | Reduce 69.34% | 2,522 | $308.27 |
| Q2 2025 | +6,467 | Add 256.42% | 8,989 | $287.35 |
| Q3 2025 | +6,079 | Add 67.63% | 15,068 | $419.21 |
Jeremy Grantham's United Therapeutics Corporation Investment FAQs
Jeremy Grantham first purchased United Therapeutics Corporation (UTHR) in Q1 2017, acquiring 1,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held United Therapeutics Corporation (UTHR) for 35 quarters since Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to United Therapeutics Corporation (UTHR) was in Q3 2020, adding 39,907 shares worth $4.03 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 15,068 shares of United Therapeutics Corporation (UTHR), valued at approximately $6.32 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.02% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in United Therapeutics Corporation (UTHR) was 39,907 shares, as reported at the end of Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.